From La Jolla Institute for Immunology: 

New research published in Science magazine will guide the development of more effective COVID-19 antibody therapies and help scientists develop effective vaccines to address emerging viral variants.

​“We were able to map the geography of Spike and understand which antibodies bind to which footprints. This map provides a reference to help predict  which antibodies are still effective against SARS-CoV-2 variants of concern like the currently surging Delta variant,” says LJI Professor Erica Ollmann Saphire, Ph.D., who leads the global effort behind this research, called the Coronavirus Immunotherapeutic Consortium (CoVIC).

CoVIC is a global, academic-industry, non-profit research collaboration that brings together scientists from around the world to understand which antibodies are most effective against the novel coronavirus SARS-CoV-2, and to streamline and accelerate the research pipeline for antibody-based therapeutics needed against SARS-CoV-2. GHR joined the Bill & Melinda Gates Foundation and the National Institutes of Health (NIH) in supporting the global partnership, headquartered at the La Jolla Institute for Immunology (LJI). ​

Learn more here. 

Over 1.5 million children lost a parent, custodial grandparent, or other relative who cared for them during the first 14 months of the COVID-19 pandemic, a first global study estimates.

From The Lancet:

"The COVID-19 pandemic priorities have focused on prevention, detection, and response. Beyond morbidity and mortality, pandemics carry secondary impacts, such as children orphaned or bereft of their caregivers. Such children often face adverse consequences, including poverty, abuse, and institutionalization. We provide estimates for the magnitude of this problem resulting from COVID-19 and describe the need for resource allocation."

Read the full study here.